Glucagon-like peptide-1 (GLP-1) agonists, the increasingly popular class of drugs for treating diabetes and obesity, may have a role to play in promoting gut healing in patients with Crohn's disease, Mount Sinai researchers believe.
Glucagon-like peptide-1 (GLP-1) agonists, the increasingly popular class of drugs for treating diabetes and obesity, may have a role to play in promoting gut healing in patients with Crohn's disease, Mount Sinai researchers believe.